Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides

Jinyuan Zhou; Erik Tryggestad; Zhibo Wen; Bachchu Lal; Tingting Zhou; Rachel Grossman; Silun Wang; Kun Yan; De Xue Fu; Eric Ford; Betty Tyler; Jaishri Blakeley; John Laterra; Peter C.M. Van Zijl

doi:10.1038/nm.2268

Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides

Jinyuan Zhou, Erik Tryggestad, Zhibo Wen, Bachchu Lal, Tingting Zhou, Rachel Grossman, Silun Wang, Kun Yan, De Xue Fu, Eric Ford, Betty Tyler, Jaishri Blakeley, John Laterra, Peter C.M. Van Zijl

Research output: Contribution to journal › Article › peer-review

317 Scopus citations

Abstract

It remains difficult to distinguish tumor recurrence from radiation necrosis after brain tumor therapy. Here we show that these lesions can be distinguished using the amide proton transfer (APT) magnetic resonance imaging (MRI) signals of endogenous cellular proteins and peptides as an imaging biomarker. When comparing two models of orthotopic glioma (SF188/V+ glioma and 9L gliosarcoma) with a model of radiation necrosis in rats, we could clearly differentiate viable glioma (hyperintense) from radiation necrosis (hypointense to isointense) by APT MRI. When we irradiated rats with U87MG gliomas, the APT signals in the irradiated tumors had decreased substantially by 3 d and 6 d after radiation. The amide protons that can be detected by APT provide a unique and noninvasive MRI biomarker for distinguishing viable malignancy from radiation necrosis and predicting tumor response to therapy.

Original language	English (US)
Pages (from-to)	130-134
Number of pages	5
Journal	Nature medicine
Volume	17
Issue number	1
DOIs	https://doi.org/10.1038/nm.2268
State	Published - Jan 2011

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm.2268

Cite this

Zhou, J., Tryggestad, E., Wen, Z., Lal, B., Zhou, T., Grossman, R., Wang, S., Yan, K., Fu, D. X., Ford, E., Tyler, B., Blakeley, J., Laterra, J., & Van Zijl, P. C. M. (2011). Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nature medicine, 17(1), 130-134. https://doi.org/10.1038/nm.2268

@article{d7b5922a5ed044ab8007f76d96215bfa,

title = "Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides",

abstract = "It remains difficult to distinguish tumor recurrence from radiation necrosis after brain tumor therapy. Here we show that these lesions can be distinguished using the amide proton transfer (APT) magnetic resonance imaging (MRI) signals of endogenous cellular proteins and peptides as an imaging biomarker. When comparing two models of orthotopic glioma (SF188/V+ glioma and 9L gliosarcoma) with a model of radiation necrosis in rats, we could clearly differentiate viable glioma (hyperintense) from radiation necrosis (hypointense to isointense) by APT MRI. When we irradiated rats with U87MG gliomas, the APT signals in the irradiated tumors had decreased substantially by 3 d and 6 d after radiation. The amide protons that can be detected by APT provide a unique and noninvasive MRI biomarker for distinguishing viable malignancy from radiation necrosis and predicting tumor response to therapy.",

author = "Jinyuan Zhou and Erik Tryggestad and Zhibo Wen and Bachchu Lal and Tingting Zhou and Rachel Grossman and Silun Wang and Kun Yan and Fu, {De Xue} and Eric Ford and Betty Tyler and Jaishri Blakeley and John Laterra and {Van Zijl}, {Peter C.M.}",

note = "Funding Information: This work was supported by the US National Institutes of Health grants EB009112, EB009731 and P41 RR015241 and by the Dana Foundation, American Physicians Fellowship and Brain Tumor Funders{\textquoteright} Collaborative. We thank J. Zhang for help in pathology experiments and M. McAllister for editorial assistance. SF188/V+ cells used in this study were a gift from J. Gallo (Temple University).",

year = "2011",

month = jan,

doi = "10.1038/nm.2268",

language = "English (US)",

volume = "17",

pages = "130--134",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides

AU - Zhou, Jinyuan

AU - Tryggestad, Erik

AU - Wen, Zhibo

AU - Lal, Bachchu

AU - Zhou, Tingting

AU - Grossman, Rachel

AU - Wang, Silun

AU - Yan, Kun

AU - Fu, De Xue

AU - Ford, Eric

AU - Tyler, Betty

AU - Blakeley, Jaishri

AU - Laterra, John

AU - Van Zijl, Peter C.M.

N1 - Funding Information: This work was supported by the US National Institutes of Health grants EB009112, EB009731 and P41 RR015241 and by the Dana Foundation, American Physicians Fellowship and Brain Tumor Funders’ Collaborative. We thank J. Zhang for help in pathology experiments and M. McAllister for editorial assistance. SF188/V+ cells used in this study were a gift from J. Gallo (Temple University).

PY - 2011/1

Y1 - 2011/1

N2 - It remains difficult to distinguish tumor recurrence from radiation necrosis after brain tumor therapy. Here we show that these lesions can be distinguished using the amide proton transfer (APT) magnetic resonance imaging (MRI) signals of endogenous cellular proteins and peptides as an imaging biomarker. When comparing two models of orthotopic glioma (SF188/V+ glioma and 9L gliosarcoma) with a model of radiation necrosis in rats, we could clearly differentiate viable glioma (hyperintense) from radiation necrosis (hypointense to isointense) by APT MRI. When we irradiated rats with U87MG gliomas, the APT signals in the irradiated tumors had decreased substantially by 3 d and 6 d after radiation. The amide protons that can be detected by APT provide a unique and noninvasive MRI biomarker for distinguishing viable malignancy from radiation necrosis and predicting tumor response to therapy.

AB - It remains difficult to distinguish tumor recurrence from radiation necrosis after brain tumor therapy. Here we show that these lesions can be distinguished using the amide proton transfer (APT) magnetic resonance imaging (MRI) signals of endogenous cellular proteins and peptides as an imaging biomarker. When comparing two models of orthotopic glioma (SF188/V+ glioma and 9L gliosarcoma) with a model of radiation necrosis in rats, we could clearly differentiate viable glioma (hyperintense) from radiation necrosis (hypointense to isointense) by APT MRI. When we irradiated rats with U87MG gliomas, the APT signals in the irradiated tumors had decreased substantially by 3 d and 6 d after radiation. The amide protons that can be detected by APT provide a unique and noninvasive MRI biomarker for distinguishing viable malignancy from radiation necrosis and predicting tumor response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=78651236770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651236770&partnerID=8YFLogxK

U2 - 10.1038/nm.2268

DO - 10.1038/nm.2268

M3 - Article

C2 - 21170048

AN - SCOPUS:78651236770

SN - 1078-8956

VL - 17

SP - 130

EP - 134

JO - Nature medicine

JF - Nature medicine

IS - 1

ER -

Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this